On Friday shares of Prothena Corporation plc (NASDAQ:PRTA) closed at $38.66. Prothena reported promising results from an early-stage study of a drug designed to treat Parkinson’s disease. Prothena said the study showed the drug, PRX002, was safe, without serious side effects, and that it reduced levels of a protein that is believed it be associated with the disease. The drug was tested on 40 healthy people, which is common in early clinical trials of experimental drugs. Prothena is conducting studies that will involve more people, including patients who suffer from the disease.
On Friday shares of Citizens Financial Group, Inc. (NYSE:CFG) closed at $24.80. Company’s EPS growth for next 5 years is recorded as 10.00%. Citizens Financial Group, Inc. (NYSE:CFG) announced that The Royal Bank of Scotland Group plc (“RBS”), through a subsidiary, has launched an underwritten public offering to sell Citizens Financial Group, Inc. common stock. CFG will not be issuing or selling common stock, and will not receive any proceeds from the offering. The number of shares of CFG common stock to be sold by RBS is expected to equal 115 million shares. In addition, RBS will grant the underwriters an overallotment option to purchase up to an additional 17.25 million shares.
Foundation Medicine, Inc. (NASDAQ:FMI) in last trading activity moved down -0.60% to close at $48.11. Company weekly performance is 1.82% while its quarterly performance stands at 119.78%. Foundation Medicine, Inc. (NASDAQ:FMI) is -11.37% away from its 52 week high. Foundation Medicine, Inc. (NASDAQ:FMI) announced that the company and its collaborators will present 20 oral and poster presentations at the 2015 United States & Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 21-27, 2015 in Boston.
CEL-SCI Corporation (NYSEMKT:CVM) has 16.70% insider ownership while its institutional ownership stands at 8.30%. In last trading activity company’s stock closed at $1.11. On March 12, Cancer immunotherapy has become word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSEMKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
On last trading day Celadon Group Inc. (NYSE:CGI) moved up 0.22% to close at $27.24. Its volatility for the week is 2.24% while volatility for the month is 2.42%. CGI’s sales growth for past 5 years was 9.10% and its EPS growth for past 5 years was 66.80%. Celadon Group Inc. (NYSE:CGI) monthly performance is 6.03%.